Hostname: page-component-76d6cb85b7-mgxrv Total loading time: 0 Render date: 2026-07-17T02:39:36.649Z Has data issue: false hasContentIssue false

Beyond COVID-19 vaccine acceptance: survey evidence from Taiwan

Published online by Cambridge University Press:  15 July 2025

Yun-Yeh Chiang
Affiliation:
Department of Political Science, National Taiwan University, Taipei City, Taiwan
Jason Kuo*
Affiliation:
Department of Political Science, National Taiwan University, Taipei City, Taiwan
*
Corresponding author: Jason Kuo; Email: jasonkuo@ntu.edu.tw
Rights & Permissions [Opens in a new window]

Abstract

Unlike many other industrial societies, the partisan fights on the vaccination against COVID-19 in Taiwan centred on its brand choice rather than acceptance. Did the incumbent DPP supporters adhere to their party line of Medigen to vaccinate against COVID-19 during the pandemic? We argue that individual COVID-19 vaccine brand choices as gradually updated judgements during the pandemic were not solely determined by the party line, but jointly shaped by the strength of party affiliation and the level of government trust to facilitate decision-making in the highly uncertain information environment at the early stage of the pandemic. More specifically, when choosing COVID-19 vaccine brand, the incumbent DPP supporters, particularly weak ones, were more likely to adhere to their party line of Medigen as they trusted government more; however, this was only for the highly uncertain first shot, due to the absence of reliable information for making informed judgements about COVID vaccine brand choice at the early stage of the pandemic, not for the informationally rich booster shot. We report empirical findings consistent with our argument from statistical analyses of original data from a survey of 1642 Taiwanese adult respondents conducted in the fall of 2022.

Information

Type
Research Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2025. Published by Cambridge University Press
Figure 0

Table 1. Demographic difference between the sample and the population

Figure 1

Table 2. Summary statistics

Figure 2

Table 3. LPM estimates for political determinants of Medigen first

Figure 3

Figure 1. Marginal effects of DPP on Medigen First by Gov Trust (95% CI).

Figure 4

Figure 2. Marginal effects of Weak DPP on Medigen First by Gov Trust (95% CI).

Figure 5

Table 4. LPM estimates for political determinants of Medigen booster

Figure 6

Figure 3. (a) Marginal effects of Medigen Before and DPP on Medigen Booster by Gov Trust (95% CI); (b) Marginal effects of Medigen Before and Weak DPP on Medigen Booster by Gov Trust (95% CI).

Figure 7

Table B1. LPM estimates of Medigen first (full results)

Figure 8

Table B2. LPM estimates of Medigen booster (full results)